Top Growth Companies With Strong Insider Ownership December 2024
Reviewed by Simply Wall St
As global markets navigate a landscape marked by rate cuts from the ECB and SNB, alongside expectations for a Federal Reserve cut, growth stocks have continued to outperform their value counterparts, with the Nasdaq Composite reaching new heights. Amidst this backdrop of economic shifts and market volatility, companies with strong insider ownership can offer unique insights into potential growth trajectories, as insiders often align their interests closely with shareholders.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| People & Technology (KOSDAQ:A137400) | 16.4% | 37.3% |
| Archean Chemical Industries (NSEI:ACI) | 22.9% | 41.3% |
| Kirloskar Pneumatic (BSE:505283) | 30.3% | 26.3% |
| Seojin SystemLtd (KOSDAQ:A178320) | 30.9% | 39.9% |
| Medley (TSE:4480) | 34% | 31.7% |
| Laopu Gold (SEHK:6181) | 36.4% | 34.2% |
| Brightstar Resources (ASX:BTR) | 16.2% | 84.5% |
| Fine M-TecLTD (KOSDAQ:A441270) | 17.2% | 131.1% |
| HANA Micron (KOSDAQ:A067310) | 18.5% | 110.9% |
| Findi (ASX:FND) | 34.8% | 112.9% |
Let's take a closer look at a couple of our picks from the screened companies.
MedinCell (ENXTPA:MEDCL)
Simply Wall St Growth Rating: ★★★★★☆
Overview: MedinCell S.A. is a pharmaceutical company based in France that focuses on developing long-acting injectables across various therapeutic areas, with a market capitalization of €491.05 million.
Operations: The company generates revenue primarily from its Pharmaceuticals segment, amounting to €13.20 million.
Insider Ownership: 15.8%
Earnings Growth Forecast: 115.4% p.a.
MedinCell shows promising growth potential with expected annual revenue growth of 62.5%, significantly outpacing the French market's 5.6%. Despite reporting a net loss of EUR 14.57 million for the recent half-year, the company anticipates reaching EUR 100 million in revenue by March 2025 and is forecasted to become profitable within three years. Although its share price has been volatile, analysts agree on a potential upside of 35.9%, trading well below estimated fair value.
- Click here to discover the nuances of MedinCell with our detailed analytical future growth report.
- Insights from our recent valuation report point to the potential undervaluation of MedinCell shares in the market.
Akeso (SEHK:9926)
Simply Wall St Growth Rating: ★★★★★★
Overview: Akeso, Inc. is a biopharmaceutical company that focuses on researching, developing, manufacturing, and commercializing antibody drugs with a market cap of HK$57.08 billion.
Operations: The company generates CN¥1.87 billion from its research, development, production, and sale of biopharmaceutical products.
Insider Ownership: 19%
Earnings Growth Forecast: 53.6% p.a.
Akeso demonstrates significant growth potential with forecasted annual revenue growth of 33.6%, surpassing the Hong Kong market's 7.8%. Recent approvals for innovative bispecific antibodies like cadonilimab and ivonescimab bolster its oncology portfolio, enhancing treatment options across multiple cancer indications. Despite recent shareholder dilution and insider selling, the company's strategic advancements in drug development and inclusion in China's National Reimbursement Drug List highlight its commercial potential. Trading at a substantial discount to estimated fair value, Akeso is poised for profitability within three years.
- Click here and access our complete growth analysis report to understand the dynamics of Akeso.
- In light of our recent valuation report, it seems possible that Akeso is trading beyond its estimated value.
Guangdong Guanghua Sci-Tech (SZSE:002741)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Guangdong Guanghua Sci-Tech Co., Ltd. is a Chinese company engaged in the production and sale of electronic chemicals, chemical reagents, and new energy materials, with a market cap of CN¥11.14 billion.
Operations: The company generates revenue of CN¥2.53 billion from its chemical industry segment.
Insider Ownership: 38%
Earnings Growth Forecast: 122.2% p.a.
Guangdong Guanghua Sci-Tech shows promising growth potential with forecasted revenue growth of 31% annually, outpacing the Chinese market average. Recent earnings indicate a turnaround, reporting a net income of CNY 6.78 million compared to last year's loss. Despite past shareholder dilution from private placements, the company raised significant capital, suggesting confidence in future prospects. However, high volatility and low return on equity forecasts remain concerns for investors evaluating its long-term stability.
- Delve into the full analysis future growth report here for a deeper understanding of Guangdong Guanghua Sci-Tech.
- The analysis detailed in our Guangdong Guanghua Sci-Tech valuation report hints at an inflated share price compared to its estimated value.
Turning Ideas Into Actions
- Access the full spectrum of 1529 Fast Growing Companies With High Insider Ownership by clicking on this link.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SZSE:002741
Guangdong Guanghua Sci-Tech
Produces and sells electronic chemicals, chemical reagents, and new energy materials in China.
High growth potential low.
